Akeso Doses First Patient in Phase II Study of Bispecific ADC Candidate in Breast Cancer

The Quick Take

• Akeso (9926.HK) dosed the first patient in a Phase II study of its bispecific ADC AK146D1 in breast cancer
• The AK146D1 trial targets TROP2 and Nectin-4 pathways combined with ivonescimab in an advanced IO2.0 strategy
• Akeso advances a dual ADC + IO treatment platform representing a differentiated cancer therapy approach

Akeso, Inc. (9926.HK), the Hong Kong-listed biopharmaceutical company, announced the dosing of the first patient in a Phase II clinical study evaluating AK146D1, a bispecific antibody-drug conjugate targeting TROP2 and Nectin-4 receptors, in combination with ivonescimab in patients with advanced breast cancer. The study designation is AK146D1-202, part of Akeso's broader IO2.0 plus ADC2.0 strategy that combines next-generation immunotherapy with antibody-drug conjugate technology. First patient dosing marks a clinical milestone that transitions a compound from preclinical development to active human efficacy and safety data generation.

Akeso's bispecific ADC platform targeting TROP2 and Nectin-4 simultaneously competes in one of the hottest areas of oncology: antibody-drug conjugates, where AstraZeneca's Enhertu and Gilead's Trodelvy have demonstrated best-in-class efficacy in breast cancer and inspired a wave of next-generation attempts. A bispecific approach — targeting two tumor antigens simultaneously — is a differentiation strategy that could provide superior tumour coverage versus monospecific ADCs. If Phase II data shows compelling efficacy, the stock could attract significant re-rating, while failures or safety signals could meaningfully compress the biotech premium currently embedded in HKEX-listed biotech valuations.

The critical forward signal is the timeline for Phase II interim data readout, which would provide the first efficacy signal from human trial results. Investors tracking HKEX biotech should also monitor the regulatory pathway: whether Akeso pursues US FDA approval alongside NMPA approval in China determines the total addressable market and partnership interest from global pharma. The macro variable for biotech valuations on HKEX is US interest rates — biotech stocks are long-duration assets whose discounted cash flows are sensitive to discount rate increases. Any FDA guidance on ADC combination therapies in breast cancer would also provide regulatory framework clarity benefiting Akeso and peers.

Synthesized from 1 source.